Estrella Immunopharma, Inc. (ESLA) — Financial statements
Income statement, balance sheet, and cash flow for Estrella Immunopharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2024 | 2022 | 2022 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 10↑59.9% | 6↑56.0% | 4 | 0.00↓100.0% | 1 | |
| General & Administrative Expenses | 0.00↓100.0% | 1↓55.7% | 3 | 0.00↓100.0% | 0.30 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 3↑15.5% | 2↓23.9% | 3↑134.0% | 1↑361.8% | 0.30 | |
| Other Expenses | 0.00 | 0.00 | 0.00↓100.0% | 0.20 | 0.00 | |
| Operating Expenses | 13↑47.7% | 9↑21.0% | 7↑365.8% | 2↓6.9% | 2 | |
| Total Costs & Expenses | 13↑47.7% | 9↑21.0% | 7↑365.8% | 2↓6.9% | 2 | |
| Operating Results | ||||||
| Operating Income | -13↓47.7% | -9↓21.0% | -7↓365.8% | -2↑6.9% | -2 | |
| Depreciation & Amortization | 0.00↑100.0% | -0.04 | 0.00↓100.0% | 0.23↓3.4% | 0.24 | |
| EBITDA | -13↓47.7% | -9↓21.0% | -7↓964.1% | -0.69↓6055.7% | -0.01 | |
| EBIT | -13↓47.7% | -9↓21.0% | -7↓698.5% | -0.92↓269.6% | -0.25 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.65↑45703.3% | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.65↑45703.3% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↑100.0% | -0.65↑54.5% | -1 | |
| Other Income / Expenses | 0.00 | 0.00 | 0.00↓100.0% | 0.65↓54.5% | 1 | |
| Income Before Tax | -13↓47.7% | -9↓21.0% | -7↓698.5% | -0.92↑45.7% | -2 | |
| Income Tax Expense | 0.00↓50.4% | 0.00↑3.9% | 0.00↓98.0% | 0.08↑134.3% | -0.24 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -13↓47.6% | -9↓21.0% | -7↓634.0% | -1.00↓302.1% | -0.25 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -13↓47.6% | -9↓21.0% | -7↓634.0% | -1.00↑40.9% | -2 | |
| Bottom-Line Net Income | -13↓47.6% | -9↓21.0% | -7↓634.0% | -1.00↓302.1% | -0.25 | |
| EPS (Basic) | -0.35↓40.0% | -0.25↓19.0% | -0.21↓23.5% | -0.17↑41.4% | -0.29 | |
| EPS (Diluted) | -0.35↓40.0% | -0.25↓19.0% | -0.21↓23.5% | -0.17↑41.4% | -0.29 | |
| Weighted Average Shares | 37↑0.4% | 37↑4.2% | 35↑510.8% | 6↓1.5% | 6 | |
| Weighted Average Diluted Shares | 37↑0.4% | 37↑4.2% | 35↑510.8% | 6↓1.5% | 6 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.